STERIS plc
NYSE:STE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (39.2), the stock would be worth $282.98 (28% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.7 | $221.8 |
0%
|
| 3-Year Average | 39.2 | $282.98 |
+28%
|
| 5-Year Average | 46.1 | $332.42 |
+50%
|
| Industry Average | 26 | $187.89 |
-15%
|
| Country Average | 19.4 | $140.18 |
-37%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$24.2B
|
/ |
Jan 2026
$707.9m
|
= |
|
|
$24.2B
|
/ |
Mar 2026
$1B
|
= |
|
|
$24.2B
|
/ |
Mar 2027
$1.1B
|
= |
|
|
$24.2B
|
/ |
Mar 2028
$1.2B
|
= |
|
|
$24.2B
|
/ |
Mar 2029
$1.2B
|
= |
|
|
$24.2B
|
/ |
Mar 2030
$1.3B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| IE |
|
STERIS plc
NYSE:STE
|
21.8B USD | 30.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.8 |
| Median | 19.4 |
| 70th Percentile | 24 |
| Max | 93.9 |
Other Multiples
STERIS plc
Glance View
Emerging as a silent pioneer in the intricate world of sterilization and infection prevention, STERIS plc has carved out a significant niche in the healthcare industry. Originally founded in 1985, the company has grown through strategic acquisitions and organic expansion. It primarily focuses on protecting patients by ensuring high standards of cleanliness and safety in healthcare environments. STERIS offers a broad array of products and services, from sophisticated sterilization equipment for hospital operating rooms to surface disinfectants and washes that keep healthcare facilities safe and clean. Their diverse portfolio ensures that they can meet the evolving needs of the global healthcare sector, which increasingly demands stringent infection control protocols. What sets STERIS apart is its innovative approach to both service and product offerings, which blend together to create comprehensive infection prevention solutions. By marrying state-of-the-art technology with a service-oriented business model, the company supports hospitals, medical-device companies, and research labs by maintaining their operational readiness and compliance with health standards. Revenue is generated through a mix of product sales as well as renewable service contracts, which guarantee recurring income. These long-term service agreements, alongside the consistent demand for advanced sterilization solutions, have enabled STERIS to sustain and even enhance its financial health while supporting the mission of safer patient care globally.